8-K/A: Jasper Therapeutics Completes Kira Pharmaceuticals Merger

Jasper Therapeutics, Inc. files an amendment to its Form 8-K to include financial statements and pro forma information related to its acquisition of Kira Pharmaceuticals.

Summary

• Jasper Therapeutics, Inc. (Jasper) has filed an amendment (Form 8-K/A) to its previous Current Report on Form 8-K.
• This amendment is to include required financial statements and unaudited pro forma financial information related to the acquisition of Kira Pharmaceuticals (Kira).
• The acquisition was completed on July 16, 2026, through a merger where Kira became a wholly owned subsidiary of Jasper.
• The filing includes audited financial statements for Kira for the fiscal years ended December 31, 2025 and 2024.
• It also includes unaudited financial statements for Kira for the six months ended June 30, 2026 and 2025.
• Additionally, unaudited pro forma condensed combined financial information for Jasper, reflecting the merger, a concurrent private placement, contingent value rights distribution, and a license agreement, is provided.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant financial disclosures of Kira Pharmaceuticals, highlighting its ongoing losses and substantial doubt about its ability to continue as a going concern prior to the merger. While the merger itself is a positive development, the underlying financial health of the acquired entity presents challenges.

Positives

• Completion of the acquisition of Kira Pharmaceuticals by Jasper Therapeutics, Inc., integrating the companies.
• Inclusion of comprehensive financial statements for Kira, providing transparency into its historical performance.
• Provision of pro forma financial information that illustrates the combined entity's potential financial position and results of operations post-merger.

Negatives

• Kira Pharmaceuticals' audited financial statements reveal significant accumulated deficits and negative operating cash flows from operations.
• Kira Pharmaceuticals' auditors raised substantial doubt about its ability to continue as a going concern prior to the merger.
• The pro forma balance sheet shows a significant combined deficit of $121,546 thousand as of June 30, 2026.
• The pro forma statement of operations for the year ended December 31, 2025, indicates a combined net loss of $206,837 thousand.

Risks

• Kira Pharmaceuticals has incurred losses since inception, resulting in an accumulated deficit of $180.8 million as of December 31, 2025, with further losses anticipated.
• The company faces risks common to the biotechnology industry, including successful technology development, obtaining additional funding, regulatory compliance, and clinical trial outcomes.
• There is uncertainty regarding when, if ever, the company will realize significant revenue from therapy sales.
• The merger with Jasper Therapeutics included a private placement of non-voting convertible preferred stock, which holders have the right to require repurchase if stockholder approval for conversion is not obtained within 12 months.

Future Outlook

The pro forma financial information provides an outlook for the combined entity post-merger, reflecting the impact of the acquisition, a concurrent private placement financing, a contingent value rights agreement, and a license agreement. This information is presented to illustrate the estimated effects of these transactions.

Industry Context

StockSavvy.ai notes that this filing is typical for a clinical-stage biopharmaceutical company undergoing a significant transaction like a merger. The inclusion of detailed financial statements for the acquired entity, Kira Pharmaceuticals, highlights the due diligence process and the financial realities of early-stage biotech companies, which often operate at a loss and require substantial capital.

Comparison to Industry Standards

• Kira Pharmaceuticals' financial situation, with significant accumulated deficits and operating losses, is common among pre-revenue biotechnology companies investing heavily in research and development.
• The need for substantial additional capital, as noted in Kira's going concern assessment, is a standard challenge in the biotech sector, often addressed through mergers, acquisitions, or significant financing rounds.
• The pro forma combined financial statements reflect the typical capital structure adjustments seen in such transactions, including the issuance of common and preferred stock and the impact of financing activities.

Corporate Governance

Related Party Transactions

• Kira Pharmaceuticals had a secured senior promissory note with Mach5 Therapeutics, Inc. (a related party), which was amended and restated, with borrowings totaling $600 thousand as of December 31, 2025. This note was settled concurrently with the asset acquisition of Mach5.
• Kira Pharmaceuticals entered into a Secured Promissory Note with Kira KMF Team LLC (a related party) for up to $0.3 million, which was later converted into ordinary shares representing 95% of the company's fully diluted equity.
• Kira Pharmaceuticals entered into a Management and Founder Incentive Agreement with Kira KMF Company LLC (KMF), an entity owned by management and founders, for monthly funding and potential contingent fees.

Stakeholder Impact

• Shareholders of Jasper Therapeutics may experience dilution if the convertible preferred stock is converted into common stock.
• Kira Pharmaceuticals' equity holders received shares of Jasper common stock and non-voting convertible preferred stock as part of the merger.
• Holders of Jasper's common stock prior to the merger are entitled to contingent value rights (CVRs) that could provide a future payout based on regulatory milestones.
• Creditors of Kira Pharmaceuticals may be impacted by the merger, with the financial statements indicating significant liabilities prior to the transaction.

Next Steps

• Jasper Therapeutics, Inc. will seek a stockholder vote to approve the conversion of the non-voting convertible preferred stock issued in the merger and private placement.
• The company will also seek shareholder approval to amend its Certificate of Incorporation to increase the authorized number of common shares.
• A resale registration statement for shares issuable upon conversion of the private placement securities is required to be filed within 90 days.
• The contingent value rights holders are entitled to a pro-rata portion of $30.0 million if a Priority Review Voucher is issued for briquilimab by December 31, 2028.

Key Dates

Recommendation

The filing details the completion of a merger and provides extensive financial information for the acquired entity, Kira Pharmaceuticals, which shows significant historical losses and going concern issues. While the merger itself is a strategic step, the combined entity's financial outlook, as presented in the pro forma statements, indicates substantial ongoing losses and a complex capital structure. The significant capital raised ($132M PIPE, $8M preferred shares, $5.1M SAFEs) is positive, but the path to profitability remains long and uncertain, warranting a 'hold' recommendation until further operational progress and financial stability are demonstrated.

Keywords

Merger, Acquisition, Financial Statements, Pro Forma, Biotechnology, Clinical Stage, SEC Filing, Kira Pharmaceuticals